A Phase 1 interventional study of Sodium ST20 in Healthy, sponsored by HemaQuest Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-08-05.
Sponsored by HemaQuest Pharmaceuticals Inc. · Phase 1 and Interventional
A safety and pharmacokinetic study of a single dose of ST20 in healthy volunteers
A Phase 1 study in healthy volunteers to assess the safety and pharmacokinetics of ST20 after oral administration of a single-dose. In addition, a comparison of the pharmacokinetics and exposure of a single dose of ST20 under fasting and non-fasting conditions will be assessed.
HemaQuest Pharmaceuticals Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
8 subjects total (6 active and 2 placebo)
Drug: Sodium ST20
single administration of oral dosage form
safety, maximum tolerated dose
Time frame: specified timepoints in the protocol
pharmacokinetics
Time frame: specified timepoints in the protocol
This study is completed, as verified in Aug 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HemaQuest Pharmaceuticals Inc.